Characterization of reverse engineered anti-PF4 stereotypic antibodies derived from serum of VITT patients.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
accepted:
31
10
2023
received:
26
05
2023
revised:
26
10
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
aheadofprint
Résumé
This study presents a novel reverse-engineering approach to generate recombinant anti-PF4 antibodies from VITT-patient sera. These antibodies recapitulate functional effects of original serum anti-PF4 clonotypes, identify key PF4 binding residues and hold promise as valuable tools to investigate VITT etiology.
Identifiants
pubmed: 37976451
pii: 498764
doi: 10.1182/blood.2023021307
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Society of Hematology.